Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

166P - Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients

Date

03 Apr 2022

Session

Poster Display session

Topics

Targeted Therapy;  Translational Research

Tumour Site

Thoracic Malignancies

Presenters

Shouzheng Wang

Citation

Annals of Oncology (2022) 33 (suppl_2): S105-S110. 10.1016/annonc/annonc865

Authors

S. Wang1, T. Xie2, Y. Wang1, X. Hao3, P. Yuan1, Q. Cao1, H. Wang2, L. Lin4, J. Ying3, J. Li3, P. Xing5

Author affiliations

  • 1 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 2 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 3 Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing/CN
  • 4 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN
  • 5 Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 166P

Background

The clinical benefits of immunotherapy are limited for unselected EGFR+ lung adenocarcinoma (LUAD). Conventional biomarkers like PD-L1 or TMB are not sufficient for these patients. Additionally, efficacy of EGFR-TKIs among EGFR+/TP53+ patients are significantly inferior to EGFR+/TP53- patients and subsequent treatment strategy are even more important. We conducted an integrated analysis to investigate the influence of TP53 mutation in immunotherapy efficacy and tumor microenvironment (TME) among EGFR+ LUAD.

Methods

A retrospective study was conducted to explore the predictive value of TP53 in clinical outcomes of immunotherapy. Analyses of genomic and transcriptomic data from TCGA database and immunohistochemistry results of tumor infiltrating immune cells (TIICs) from paired samples at baseline and after resistance to EGFR-TKIs from the local cohort were conducted to explore the changes in TME.

Results

A total of 42 EGFR+ LUAD patients were included in the retrospective study. The median PFS of TP53+ patients was significantly longer than that of TP53- patients (6.7 vs. 2.6 months; p= 0.003). Multivariate Cox regression analysis indicated that only TP53 mutation was significantly associated with superior PFS (HR, 0.38; 95%CI, 0.17-0.84; p = 0.016). TCGA data analysis indicated that there were no significant differences in PD-L1 expression, TMB and fractions of TIICs between TP53+ and TP53- groups. Among local cohort, there were also no significant differences in tumor infiltrating immune cells between TP53+ and TP53- patients in both baseline and re-biopsy samples. However, analysis of 20 paired samples revealed that the median density of CD8+ T cell increased significantly during EGFR-TKI treatment only in TP53+ patients (re-biopsy vs. baseline: 14.6 vs. 3.2; p = 0.008), not in TP53- patients (21.9 vs. 13.6; p = 0.422).

Conclusions

TP53 mutation is an independent predictive factor of superior efficacy of anti-PD-1/PD-L1 treatment among EGFR+ LUAD patients, which may result from the trend to be more inflamed in TME during EGFR treatment among TP53+ patients.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.